Alzheimer's & Dementia

Alzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills. Alzheimer’s is the most common cause of dementia among older adults. Dementia is the loss of cognitive functioning—thinking, remembering, and reasoning—and behavioral abilities to such an extent that it interferes with a person’s daily life and activities.

GLP-1 Receptor Agonists in Alzheimer’s Disease: Emerging Off-Label Neuroprotective Potential

GLP-1 receptor agonists show strong preclinical neuroprotective potential in Alzheimer’s disease through effects on insulin signaling, neuroinflammation, amyloid, tau, and brain metabolism. Human evidence remains mixed, with observational studies suggesting lower dementia risk but randomized trials yet to demonstrate a clinically meaningful disease-modifying benefit.

Dementia with Lewy Bodies

Alzheimer's Disease Symptoms

Parkinson's Compared to Dementia with Lewy Bodies (DLB)

Transcutaneous Electrical Nerve Stimulation for Dementia

Does Depression and Anxiety Increase the Risk of Dementia?

Stem Cell Therapy for Alzheimer's

What is Dementia?

Dementia Treatment

Integrated PET/MR for Alzheimer’s Disease

Dementia Symptoms

Diet and Alzheimer's Disease

See more featured articles »

Amyloid Cascade Hypothesis

Alzheimer's Disease Prevention

AAM - Genetics of Alzheimer's

Does Type 2 Diabetes Increase the Risk of Alzheimer’s Disease?

Is Alzheimer's Disease Transmissible?

Childhood Dementia Causes

Stress and Alzheimer's Disease

Alzheimer’s tangles and plaques: what’s the difference?

Antibody Research and Alzheimer’s Disease

Alzheimer’s Disease and Calcium Supplements

Alzheimer's Disease and the Microbiome

Designing Dementia-Friendly Environments

Migraines and Dementia

Does Herpesvirus Cause Alzheimer's?

Alzheimer’s Disease and Gingko Biloba

Types of Alzheimer's Disease

AAM - Air pollution and Alzheimer's

AAM - The Search for a Cure to Alzheimer's

Alzheimer's and Veganism

Alzheimer's Disease Treatments

What is Mixed Dementia?

Mythbusting: Misconceptions in Dementia

Gender and Alzheimer’s Risk

Do Antioxidants Benefit Patients with Alzheimer’s and Parkinson’s?

Dementia Prevention

Alzheimer's Disease Causes

Mixed Dementia Prevention and Treatment

Alzheimer's Disease and Sleep Disruption

Alzheimer’s Disease | Definition, Causes, Diagnosis & Treatment

Bright Light Therapy and Dementia

Can Happiness Protect You from Dementia?

Mixed Dementia Symptoms and Diagnosis

What are Amyloid Plaques?

Pollution and Alzheimer's

Can Statins Protect Against Alzheimer’s Disease?

Alzheimer's Disease Questions

Aromatherapy for Dementia

Dementia Diagnosis

Dancing Through Dementia: How Movement Aids Memory and Mood

Coconut Oil and Dementia

Inflammation and Alzheimer's Disease

Biomarkers for Alzheimer's Disease

Does Type 2 Diabetes Increase the Risk of Alzheimer’s Disease?

Childhood Dementia Signs and Symptoms

Differences Between Alzheimer's and Dementia

Antidepressants and Dementia: Is There a Link?

Omega-3 and Alzheimer’s Disease

Alzheimer's Disease Diagnosis

Alzheimer's Disease Epidemiology

What Causes Dementia?

Latest Alzheimer's & Dementia News and Research

Brain shrinkage biomarker may predict early-onset Alzheimer’s progression

In people diagnosed with early-onset Alzheimer's disease, a biomarker tool that detects shrinkage of the brain's gray matter may predict how quickly someone may progress from mild cognitive impairment (MCI) to dementia, according to a new study published August 26, 2026, in Neurology, an official journal of the American Academy of Neurology.

27 Aug 2026

Brain atrophy on MRI could help predict Alzheimer’s progression

Mass General Brigham Neuroscience Institute researchers have found that a pattern of brain atrophy visible on MRI could help predict how quickly people with early-onset Alzheimer's disease progress from mild cognitive impairment to dementia.

27 Aug 2026

Faulty myelin-making brain cells may help drive cognitive decline with age

Researchers found that greater age-related cognitive decline was associated with more dysfunctional oligodendrocytes, reduced NRF2 expression, smaller myelinated axons, and abnormally thicker myelin in human white matter. Experiments in mice showed that deleting NRF2 specifically from oligodendrocytes reproduced key white matter abnormalities and reduced cognitive improvement over time, implicating this pathway in cognitive aging.

26 Aug 2026

A major NFL brain study puts new numbers on the burden of CTE

Researchers analyzed 1,712 former NFL players who died between 2008 and 2021, including 338 brain donors, to estimate the possible prevalence of chronic traumatic encephalopathy (CTE) at death and its association with dementia. At least 24.5% of players who died from 2016 to 2021 had confirmed CTE, while stage IV CTE among brain donors was associated with a 44% higher risk of clinician-adjudicated dementia.

26 Aug 2026

Nanoparticles regenerate neurons and improve cognition in Alzheimer’s mice

The adult human brain has limited capacity to repair or regenerate neurons lost to Alzheimer's disease, the most common type of dementia.

26 Aug 2026

Specific brain regions found more vulnerable to dementia with Lewy bodies

Dementia with Lewy bodies is one of the most common forms of dementia in older adults, after Alzheimer's disease.

26 Aug 2026

Molecular switch ERBB4 linked to broad range of Alzheimer's pathologies

What if amyloid plaques are not the whole story of Alzheimer's disease? New research suggests that a broad range of Alzheimer's pathologies may be orchestrated by a molecular switch called ERBB4 when it turns on in the wrong neurons.

26 Aug 2026

Hormone replacement therapy may reduce dementia risk for some women

Hormone replacement therapy (HRT) may reduce the risk of dementia, particularly for certain groups of women - according to a study from the University of East Anglia and the University of Exeter.

26 Aug 2026

Researchers find alarming rates of CTE in former football players

In a new study from Mass General Brigham, Boston University (BU), and the Concussion & CTE Foundation, researchers found evidence that at least 1-in-4 former NFL players who died between 2016 and 2021 had chronic traumatic encephalopathy (CTE) at the time of their death, a much higher prevalence compared to the general population.

25 Aug 2026

Novel blood-based method diagnoses Alzheimer’s disease with high accuracy

Alzheimer's disease (AD) accounts for 60–80% of global dementia cases, with its core pathological feature being the misfolding and aggregation of β-amyloid (Aβ) proteins in the brain.

25 Aug 2026

Dysfunctional myelin-producing brain cells contribute to age-related cognitive decline

Brain cells that produce the protective coating around nerve fibers can become dysfunctional with age and may actively contribute to cognitive decline, according to new research.

25 Aug 2026

Study reveals high prevalence of chronic traumatic encephalopathy among former NFL players

At minimum, nearly a quarter of all former National Football League (NFL) players who died from 2016 to 2021 had confirmed chronic traumatic encephalopathy (CTE) – a neurodegenerative disease linked to repeated head impacts – at death, finds a study published by The BMJ today.

25 Aug 2026

What decades of wine research can, and cannot, tell us about health

A narrative review found that moderate wine intake has repeatedly been associated with lower all-cause and cardiovascular mortality, with proposed mechanisms involving ethanol and grape-derived polyphenols, but the evidence remains largely observational and cannot establish causation. The authors argue that drinking pattern, beverage type, age, cancer risk, and risk-modeling choices all influence how the J-shaped association should be interpreted and how alcohol guidelines are developed.

25 Aug 2026

The diet-Alzheimer’s connection is more complicated than “eat this, avoid that”

A mini-review finds that dietary patterns may influence Alzheimer’s disease through interconnected pathways involving neuroinflammation, insulin resistance, oxidative stress, blood-brain barrier dysfunction, homocysteine, and the gut-brain axis. The authors argue that genetics, sex, age, physical activity, and socioeconomic context may modify these relationships, supporting more individualized approaches to nutrition research and dementia prevention.

25 Aug 2026

Shared protein pathology redefines treatment for multiple neurodegenerative diseases

On the surface, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and limbic-predominant age-related TDP-43 encephalopathy (LATE) might seem like unrelated diseases.

24 Aug 2026

Researchers explore the link between tau levels and depressive symptoms in older people

During typical aging and Alzheimer's disease progression, higher levels of a protein called tau are associated with more depressive symptoms.

24 Aug 2026

Older brains' language processing network remains resilient to aging

As people age, many cognitive functions tend to decline. Brain scanning studies have revealed corresponding changes in the function of a brain network that is involved in many of these cognitive functions, including working memory and problem-solving.

24 Aug 2026

Disrupted brain-immune signaling may help drive neurodegeneration

A Cell perspective argues that neurodegeneration can emerge from disrupted communication between neural and immune networks, with peripheral immunity, microglia, and gene-regulatory programs all shaping disease processes. The authors propose that restoring immune homeostasis and recalibrating neuroimmune circuits could create new therapeutic and diagnostic opportunities, while emphasizing that many mechanisms remain unresolved in humans.

24 Aug 2026

FDA clears innovative blood test for earlier Alzheimer's diagnosis

The U.S. Food and Drug Administration (FDA) has cleared for marketing an innovative blood test with underlying technology invented at Washington University School of Medicine in St. Louis for the early diagnosis of Alzheimer's disease.

21 Aug 2026